Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231166
Status:
COMPLETED
Last Update Posted:
2018-10-11
First Post:
2005-09-30
Brief Title:
Safety Efficacy Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase I Dose-finding Trial of HCD122 an Anti-CD40 Monoclonal Antibody in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy CHIR1212-C12101
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the highest tolerated dose safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None